Evidence map›Paper›PMID 36451749›Full record

ArticleHeliyon2022

Evaluating the clinical significance of

Yahia Moualla, Faten Moassass, Bassel Al-Halabi, Walid Al-Achkar, Michael Georgeos, Haissam Yazigi, Atieh Khamis

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Yahia MouallaDepartment of Laboratory Diagnosis, Faculty of Pharmacy, Tishreen University, Ministry of Higher Education, Lattakia, Syria.
Faten MoassassDepartment of Molecular Biology and Biotechnology, Human Genetics Division, Atomic Energy Commission, Damascus, Syria.
Bassel Al-HalabiDepartment of Molecular Biology and Biotechnology, Human Genetics Division, Atomic Energy Commission, Damascus, Syria.
Walid Al-AchkarDepartment of Molecular Biology and Biotechnology, Human Genetics Division, Atomic Energy Commission, Damascus, Syria.
Michael GeorgeosDepartment of Hematology and Oncology, Faculty of Medicine, Tishreen University, Ministry of Higher Education, Lattakia, Syria.
Haissam YazigiDepartment of Laboratory Diagnosis, Faculty of Medicine, Tishreen University, Ministry of Higher Education, Lattakia, Syria.
Atieh KhamisDepartment of Laboratory Diagnosis, Faculty of Pharmacy, Tishreen University, Ministry of Higher Education, Lattakia, Syria.
Latakia University · SYAtomic Energy Commission of Syria · SY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The FMS-like tyrosine kinase-3 internal tandem duplication (

Indexed as

Acute myeloid leukemia (AML)EFSFLT3-ITD mutationNovel mutationPrognosis

Identifiers

PMID36451749
PMCPMC9703599
OpenAlexW4310249372

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.